Jul 14, 2026 06:55AM
May 26, 2026 07:15AM
May 26, 2026 07:15AM
May 21, 2026 11:27PM
May 21, 2026 11:27PM
May 21, 2026 04:01PM
May 21, 2026 04:01PM NervGen Announces Proposed Public Offering of Securities
May 18, 2026 07:15AM
Apr 27, 2026 07:30AM
Apr 27, 2026 07:30AM
Apr 13, 2026 07:45AM
Apr 13, 2026 07:45AM
Apr 7, 2026 12:26PM
Apr 7, 2026 07:30AM NervGen gets FDA alignment for phase 3 spinal cord injury study
Apr 7, 2026 07:30AM
Apr 7, 2026 07:30AM
Mar 31, 2026 07:45AM
Mar 12, 2026 04:15PM
Mar 12, 2026 04:15PM
Mar 4, 2026 07:31AM
Mar 4, 2026 07:30AM NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
Feb 18, 2026 07:30AM
Feb 12, 2026 04:15PM
Feb 12, 2026 04:15PM
Feb 11, 2026 07:00AM
Feb 9, 2026 07:00AM
Feb 9, 2026 07:00AM
Jan 20, 2026 07:00AM NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
Jan 8, 2026 06:30AM
Mar 25, 2025 08:30AM
Jul 28, 2022 10:38AM
Jan 10, 2022 07:30AM
Jul 9, 2019 10:52AM
Jun 10, 2019 07:00AM
Jan 6, 2017 04:05PM Innovus Pharma Expands its Executive Management Team with the Addition of Randy Berholtz as its Executive Vice President, Corporate Development and General Counsel

325,890 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All